Organization · Venture Capital
Linc AB
Linc AB is a Stockholm-based investment company focused on the Nordic Life Science sector, primarily investing in pharmaceuticals and medical technology. It operates as a publicly listed holding company, making both private and public investments.
Overview
What Linc AB does
What Linc AB is
Linc AB is a Stockholm-based investment company focused on the Nordic Life Science sector, primarily investing in pharmaceuticals and medical technology. It operates as a publicly listed holding company, making both private and public investments.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 1991
- Approximate age
- About 35 years
- Structured capabilities
- Funder
- Last reviewed
- April 22, 2026
Official channels
Find Linc AB elsewhere
Open the official website or a supported primary organization account.
Capability profile
Linc AB as a funder
Investment thesis
Linc AB focuses on investing in and developing small- and mid-cap life-science companies with global potential, primarily in pharmaceuticals and medical technology. The firm adopts a long-term, active-owner model, targeting both private and public companies within the Nordic region and beyond.
Focus narrative
Linc invests in product-oriented companies within the Nordic Life Science sector, specifically targeting pharmaceuticals and medical technology. The investment range typically spans from 25 to 250 million SEK, with initial investments often being smaller and followed by larger subsequent investments. Linc aims to be one of the larger investors in the companies it supports, ensuring a substantial impact on their growth and development.
Value beyond capital
Linc AB adds value to its portfolio companies through active ownership and strategic guidance, leveraging its extensive experience in the life science sector. The firm aims to ensure meaningful influence by being one of the larger investors, providing not only capital but also expertise in navigating the complexities of the pharmaceuticals and medical technology industries.
Terms and economics
- Typical check
- $2,500,000–$25,000,000
- Sweet spot
- $10,000,000
Focus and fit
- Stages
- Pre-seed · Seed · Series A · Series B · Series C · Growth Equity
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 20
- Recorded notable exits
- Calliditas Therapeutics
Portfolio context
Linc's portfolio includes notable companies such as: Arcoma: A Swedish provider of complete radiology solutions used in clinical applications within radiology. Cinclus Pharma: A clinical-stage pharmaceutical company developing a treatment for gastroesophageal reflux disease (GERD). Egetis Therapeutics: An innovative company focused on developing integrated therapeutic solutions. MedCap: A life science investment/holding company, constituting a significant portion of Linc's assets. Sedana Medical: Specializes in inhalation sedation products, contributing to Linc's diverse portfolio.
Common questions
What to know about Linc AB
Upseed classifies Linc AB under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 22, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.